Addition of Metformin to Concurrent Chemoradiation in Patients With Locally Advanced Non-Small Cell Lung Cancer: The NRG-LU001 Phase 2 Randomized Clinical Trial.

ABSTRACT:

Importance

Non-small cell lung cancer (NSCLC) has relatively poor outcomes. Metformin has significant data supporting its use as an antineoplastic agent.

Objective

To compare chemoradiation alone vs chemoradiation and metformin in stage III NSCLC.

Design, setting, and participants

The NRG-LU001 randomized clinical trial was an open-label, phase 2 study conducted from August 24, 2014, to December 15, 2016. Patients without diabetes who were diagnosed with unresectable stage III NSCLC were stratified by performance status, histology, and stage. The setting was international and multi-institutional. This study examined prespecified endpoints, and data were analyzed on an intent-to-treat basis. Data were analyzed from February 25, 2019, to March 6, 2020.

Interventions<

SUBMITTER: Skinner H 

PROVIDER: S-EPMC8323052 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature